Rong Chen becomes Chief Medical Officer at CASI Pharmaceuticals

He will lead the company's clinical and regulatory activities in North America and Greater China

CASI Pharmaceuticals, a biopharmaceutical company dedicated to the acquisition, development and commercialisation of cancer therapeutics with a commercial focus on China, has appointed Rong Chen as Chief Medical Officer.

Chen brings more than 20 years of experience in the areas of pharmaceutical clinical development and regulatory affairs to the Rockville, Maryland, US-based company.

Prior to joining CASI, Chen was Area Medical Director and Chief Medical Governance Officer at GSK China/Hong Kong Area and in 2010 was promoted to VP, Head of Regulatory Centre of Excellence, Company Representative having overall responsibility for the registration of drug and vaccine products.

Before working at GSK, Chen was Medical Director, Global Medical Expert at Bayer-Schering Pharma Asia Pacific Area and from 2001–2005 was Medical Director at Sanofi China.

You may also like

Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company

The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
Packaging

Dual-chamber packaging systems as a simplification factor in the supply chain

Dual-chamber packaging solutions could represent a new frontier also to package parenteral drugs, simplifying the supply chain through reconstitution, potentially making logistics more flexible and efficient, says Cecilia Bassi, Product Manager at Bormioli Pharma
Regulatory

Pfizer gains European Commission approval for haemophilia A and B drug, Hympavzi

The subcutaneous therapeutic is the first and only anti-tissue factor pathway inhibitor approved for the treatment of haemophilia A or B, and is available in an auto-injector format
Subscribe now